TY - JOUR
T1 - Intracoronary and systemic melatonin to patients with acute myocardial infarction
T2 - protocol for the IMPACT trial
AU - Løvland Halladin, Natalie
AU - Busch, Sarah Ekeløf
AU - Jensen, Svend Eggert
AU - Hansen, Henrik Steen
AU - Zaremba, Tomas
AU - Aarøe, Jens
AU - Rosenberg, Jacob
AU - Gögenur, Ismail
PY - 2014/2
Y1 - 2014/2
N2 - Ischaemia-reperfusion injury following acute myocardial infarctions (AMI) is an unavoidable consequence of the primary percutaneous coronary intervention (pPCI) procedure. A pivotal mechanism in ischaemia-reperfusion injury is the production of reactive oxygen species following reperfusion. The endogenous hormone, melatonin, works as an antioxidant and could potentially minimise the ischaemia-reperfusion injury. Given intracoronarily, it enables melatonin to work directly at the site of reperfusion. We wish to test if melatonin, as an antioxidant, can minimise the reperfusion injury following pPCI in patients with AMI.
AB - Ischaemia-reperfusion injury following acute myocardial infarctions (AMI) is an unavoidable consequence of the primary percutaneous coronary intervention (pPCI) procedure. A pivotal mechanism in ischaemia-reperfusion injury is the production of reactive oxygen species following reperfusion. The endogenous hormone, melatonin, works as an antioxidant and could potentially minimise the ischaemia-reperfusion injury. Given intracoronarily, it enables melatonin to work directly at the site of reperfusion. We wish to test if melatonin, as an antioxidant, can minimise the reperfusion injury following pPCI in patients with AMI.
M3 - Journal article
C2 - 24495883
VL - 61
SP - A4773
JO - Danish Medical Bulletin (Online)
JF - Danish Medical Bulletin (Online)
SN - 1603-9629
IS - 2
ER -